45 results about "Renal tissue" patented technology

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

The invention relates to the technical field of surgical planning, in particular to a kidney tumor accurate resection path planning method and system based on three-dimensional modeling, and the method comprises the following steps: obtaining a kidney tissue tumor surface area, extracting a line segment towards a renal gate direction, extending a direction vector, constructing a passing guide line, and continuing a path to a compression direction; extracting a blood vessel crossing path section, dividing an interference area, adjusting the direction of a turning section, connecting a tumor and a renal gate, and generating a resection path planning result set. According to the method, by constructing a direction line segment set extending along a structure compression trend, advancing a path space trend segment by segment, combining a replacement mechanism of regions with inconsistent directions, depending on density division of crossing edge point segments, defining the distribution position of a traffic limited region, adjusting repeated turning segments through direction lines, and eliminating path fluctuation and turn-back interference, the traffic limited region is determined. The extending direction penetrates through the tumor center and is connected with the starting point path, the path track integrally keeps smooth extension, the space layout is more ordered, and the matching performance of the passing line segment structure is enhanced.

The present disclosure provides an oligonucleotide conjugate, which is obtained by covalently linking a kidney-targeting polypeptide as a ligand to an oligonucleotide molecule capable of inhibiting the expression of a target gene via a linker group. The oligonucleotide conjugate has affinity to a cell receptor present on a kidney target cell, and can selectively and effectively reduce or inhibit the expression of a target gene in the kidney of a subject (e.g., a human or an animal). The oligonucleotide conjugate or pharmaceutical composition provided by the present disclosure can effectively treat and / or prevent a pathological condition or disease caused by abnormal expression of a specific gene in kidney tissue cells.

The invention belongs to the technical field of intelligent medical treatment and clinical decision, and particularly relates to an idiopathic membranous nephropathy prognosis prediction method and system based on deep learning and a cross-modal attention mechanism. In order to realize accurate prognosis evaluation of IMN, depth features of a kidney tissue pathological image are automatically extracted through a deep learning technology and are innovatively and deeply fused with clinical data of a patient, and finally a high-precision and explainable intelligent prediction model is constructed to guide clinical early intervention and individualized treatment decision.

The invention discloses a biomarker for detecting renal fibrosis, application and a system, and relates to the technical field of biological medicines. The invention relates to a biomarker for detecting renal fibrosis. The biomarker comprises urinary copper cyanin. Compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin has the following three advantages: 1, compared with the conventional diagnostic marker (such as eGFR, RBP, NAG and the like), the urocyanin is more sensitive to diagnosis of renal interstitial fibrosis and fibrosis severity; secondly, compared with traumatic renal tissue pathologic biopsy, urine is used as a diagnosis medium, so that true noninvasive effect can be realized, and no harm is caused to the body health of a patient; and thirdly, compared with detection means such as iconography, the method for detecting the urinary cupreocyanin marker is lower in cost, more flexible, high in timeliness and easier to popularize.

The invention relates to heterobacterium faecalis, in particular to application of heterobacterium faecalis DSM 13633 or a culture solution thereof in preparation of a medicine for preventing or treating diabetic nephropathy. The invention proves that the urine volume of a mouse with diabetic nephropathy can be reduced by the heterobacterium faecalis DSM 13633, and the levels of urinary albumin, urine creatinine and urea nitrogen can be reduced, so that the Allobacter sterilicis can be used for improving the renal function impairment induced by hyperglycemia. Meanwhile, the pathological evaluation of kidney tissue shows that the Allobaculum stericolicis can be used for improving the renal lesion of the hyperglycemia mouse. According to the present invention, with the application of the Allobaculum stericoranis, the mRNA expression level of M1 type macrophage markers (Il6, Il1beta, iNOS) in the diabetic mouse kidney tissue can be reduced, the mRNA expression level of M2 type macrophage markers (Arg1, Il10, CD206) can be increased, and the results show that the Allobaculum stericoranis can alleviate the hyperglycemia induced renal tissue inflammation state;

The application provides a biomarker combination for non-invasive diagnosis of IgA nephropathy, comprising IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89. The application also provides an enzyme-linked immunoassay kit for auxiliary diagnosis of IgA nephropathy, which can jointly detect the levels of IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89. The application further provides an evaluation method for case damage of kidney tissue, which is based on the joint detection of the levels of IgA-IgG immune complexes, IgG-IgA1 immune complexes, and IgA immune complexes combined with CD89 in a sample, calculates a multi-index prediction score, and sets an evaluation threshold to determine whether short glomeruli have pathological damage. When the biomarkers are used for auxiliary diagnosis of IgA nephropathy, the biomarkers not only have the characteristics of non-invasiveness, but also have higher sensitivity, higher specificity and higher stability, and have clinical application value.

The invention relates to the technical field of biological medicine, in particular to a biomarker related to early diagnosis of diabetic nephropathy and application of the biomarker. The invention discloses and verifies the application value of the TRPV2 protein as the biomarker for early diagnosis of diabetic nephropathy for the first time. Clinical queue research proves that compared with a healthy control group, the expression level of TRPV2 protein in proximal renal tubules of kidney tissues of DKD patients is remarkably increased and is continuously increased along with pathological grading progress, TRPV2 protein expression of III-IV-level DKD patients is remarkably higher than that of I-II-level DKD patients, and the TRPV2 protein expression of III-IV-level DKD patients is closely related to the degree of renal function impairment; meanwhile, the AUC of a working characteristic curve of a subject can reach 0.9077 to 0.9291. Therefore, the TRPV2 protein provided by the invention can accurately identify DKD patients and healthy people.

The present application relates to the field of drug delivery technology and chronic kidney disease treatment, in particular, a kidney tissue targeted chronic kidney disease treatment drug nano delivery system, which solves the problems of poor targeting, low bioavailability, obvious side effects of existing chronic kidney disease treatment drugs, and insufficient responsiveness and poor safety of existing nano delivery systems. The system comprises a double-responsive nano carrier, an anti-kidney fibrosis drug and a targeting mediation layer. The double-responsive nano carrier is based on methoxy polyethylene glycol modified chitosan-polylactic acid copolymer, contains pH-sensitive hydrazone bonds and redox-sensitive disulfide bonds, and has a core-shell structure. The surface of the carrier is covalently connected with CD13 receptor affinity peptides, and is coated with a polylysine modified hyaluronic acid targeting mediation layer. The drug is pirfenidone or mycophenolate mofetil, which is covalently combined with the carrier through a disulfide bond. The system can realize precise enrichment of kidney lesions and double-responsive controlled drug release, improve the treatment effect, and reduce systemic and local toxicity.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

This invention discloses a method for restoring TREM2 in the preparation of diabetic nephropathy using luteolin. + This invention relates to the application and research methods of macrophage functional drugs, and pertains to the field of biomedical technology. Through the technical solution of this invention, luteolin is used for the intervention of diabetic nephropathy, achieving the effect of regulating TREM2. + Targeted regulation of the key pathological link of macrophage dysfunction; by increasing TREM2 + The number and functional status of macrophages are improved, enhancing their ability to eliminate apoptotic cells, reducing the level of renal tissue cell apoptosis and immune inflammatory damage; thereby alleviating the progression of kidney damage in diabetic nephropathy.

This invention discloses Astragalus polysaccharide, extracted from Astragalus membranaceus. The average molecular weight of this Astragalus polysaccharide is 8-12 kDa, and its monosaccharides are mainly composed of galacturonic acid, glucose, galactose, and arabinose. This Astragalus polysaccharide is a GalA-type acidic polysaccharide that effectively reduces the deposition of immune complexes and the release of pro-inflammatory factors in renal tissue by regulating signaling pathways such as cGAS-STING. Simultaneously, it improves glomerular filtration function by stabilizing the podocyte cytoskeleton structure, exhibiting a synergistic protective therapeutic advantage. This invention also discloses a method for preparing this Astragalus polysaccharide.

The invention belongs to the technical field of biological medicines, and relates to application of Kir4.2 in treatment of renal fibrosis. The invention discovers that the expression level of the Kir4.2 protein (formed by KCNJ15 gene coding) in renal tissues of a fibrotic mouse is obviously lower than that of a wild type mouse for the first time, and the difference has statistical significance; moreover, after the Kir4.2 is specifically knocked out of the renal proximal tubule, renal fibrosis under a UUO and FA induction model can be aggravated, and the fibrosis process of human renal tubule epithelial cells induced by TGF-beta1 in vitro can be remarkably reversed by overexpression of the Kir4.2. Therefore, Kir4.2 can be used as a drug, a drug target or a target gene in gene therapy, is applied to prevention, alleviation and treatment of renal fibrosis, and can provide a new strategy for prevention and treatment of renal fibrosis. The invention further provides a construction method of the kidney proximal tubule specificity Kir4.2 knockout animal model, and the constructed animal model can be used for researching renal fibrosis pathogenesis and screening drugs for preventing, relieving or / and treating renal fibrosis and has a wide application prospect.

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis

The invention belongs to traditional Chinese medicines, and discloses a traditional Chinese medicine compound composition for treating diabetic nephropathy and a quality evaluation method thereof, and the traditional Chinese medicine compound composition comprises astragalus membranaceus, prepared rehmannia root, dogwood, poria cocos, gordon euryale seed, cherokee rose fruit, semen cuscutae, herba lycopi, salvia miltiorrhiza and rheum officinale. The traditional Chinese medicine composition can improve weight loss and blood sugar increase caused by diabetic nephropathy, effectively relieve renal dysfunction and kidney tissue pathological conditions, relieve the degree of pathological injuries such as inflammation and fibrosis in kidney tissue, and finally achieve the effect of treating diabetic nephropathy. The method comprises the following steps: detecting by adopting a high performance liquid chromatography, establishing a characteristic spectrum, obtaining 22 common characteristic peaks, identifying the characteristic peaks by adopting a high-resolution mass spectrum, selecting 7 characteristic components on the basis of the characteristic spectrum, and establishing a content determination method for simultaneously determining the 7 components. The traditional Chinese medicine composition has important significance for controlling the quality of the traditional Chinese medicine composition for treating diabetic nephropathy.

The invention discloses a biomarker for diagnosing diabetic nephropathy and application, and relates to the technical field of biological medicine. The invention relates to a biomarker for diagnosing diabetic nephropathy. The biomarker comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or the urine MBP-1 / urine creatinine marker has high identification efficiency: when the urine MBP-1 or the urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity both exceed 0.85, and two diseases can be efficiently distinguished. Only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operation such as kidney biopsy is avoided, the patient acceptability is high, and repeated detection can be conducted to dynamically track the illness state; special equipment is not needed, and clinical application and popularization are facilitated. Kidney tissue immunofluorescence verification shows that MBP-1 is massively deposited in DKD glomerulus and does not exist in NDRD, and local pathological changes of the kidney can be directly reflected.

The invention discloses a nano multi-drug synergistic targeting delivery system based on bilirubin prodrugs and a preparation method of the nano multi-drug synergistic targeting delivery system. The system is formed by self-assembly of an amphiphilic conjugate, the conjugate takes a second-generation lysine dendrimer (G2K) as a hydrophilic skeleton, and the branched end of the conjugate is covalently modified with a hydrophobic antioxidant bilirubin (Br) through a reactive oxygen species (ROS)-sensitive thioketal bond (TK) and is further coupled with a targeting ligand serine (L-serine). The delivery system can specifically recognize damaged kidney tissue, and accurate enrichment of therapeutic drugs in acute kidney injury (AKI) focuses is achieved. After entering a focus, the carrier drives the explosive release of the medicine by utilizing a dual response mechanism of TK bond breakage and bilirubin polarity overturning, and meanwhile, the endogenous anti-oxidation effect of carrier components is exerted. The delivery system provided by the invention has the characteristics of high drug loading capacity, good biocompatibility, strong targeting property and multi-drug synergistic treatment, and has a wide application prospect in the field of kidney disease treatment.

The invention provides a method for synchronously measuring main components of herba epimedii in a sample based on an LCMS / MS (Liquid Chromatography Mass Spectrometry / Mass Spectrometry) technology. Performing LC-MS / MS analysis on the reference substance mother liquor, recording the retention time, parent ion, characteristic daughter ion and characteristic fragment ion information of each reference substance, and establishing a qualitative recognition database; preparing a test solution of the sample; wherein the sample is at least one of a herba epimedii raw material medicine, a traditional Chinese medicine preparation containing herba epimedii and a biological sample; performing LC-MS / MS analysis on the test solution to obtain a mass spectrum ion chromatogram; comparing the mass spectrum ion chromatogram with a qualitative identification database, and qualitatively judging whether the test solution contains a target component corresponding to the reference substance or not. The method can be used for synchronously and qualitatively detecting preparations such as herba epimedii raw material medicine, GuShukang capsules and Xintong oral liquid as well as in-vivo biological samples such as serum, liver tissue and kidney tissue, and in-vitro-in-vivo full-chain component identification is realized.

The application belongs to the technical field of medicine, and mainly relates to application of echinocystic acid in preparation of a medicine for treating sepsis. A mouse sepsis model is established by using a cecal ligation and puncture (CLP) method, the influence of the echinocystic acid on sepsis mice and sepsis kidney injury is observed, and a human renal tubular epithelial cell (HK-2) is stimulated by using a lipopolysaccharide to evaluate the influence of the echinocystic acid on cell inflammation and apoptosis. The results show that the echinocystic acid can reduce the related symptoms of the sepsis mice, reduce kidney injury of the sepsis mice by inhibiting CLP-mediated kidney tissue inflammation and apoptosis, and improve the survival rate. Meanwhile, the echinocystic acid can effectively weaken LPS-induced inflammation and apoptosis of the HK-2 cells. It is shown that the echinocystic acid has a good application prospect in treatment of sepsis and sepsis-related acute kidney injury.

The application discloses application of a Ptprj agonist GJ103 in preparation of a medicine for preventing and / or treating renal fibrosis. It is disclosed that active up-regulation of Ptprj can obviously inhibit proliferation and activation of fibroblasts caused by TGF-beta 1, and knockout of Ptprj aggravates renal fibrosis caused by UUO and promotes activation of fibroblasts. As a Ptprj small molecule agonist, GJ103 treatment not only obviously inhibits renal fibroblast activation induced by TGF-beta 1, but also obviously improves pathological damage of renal tissues caused by obstruction and ischemia and reduces deposition of extracellular matrix. The results show that Ptprj plays a protective role in the process of renal fibrosis, and its agonist GJ103 provides a new target for prevention and diagnosis and treatment of CKD.

This invention discloses the application of targeting and inhibiting the MSR1-PI3K / AKT signaling pathway in the treatment of kidney injury induced by polylactic acid (PLA) microplastic particles (PLMPs). The study shows that oligomeric PLA MPs recognize and activate the downstream PI3K / AKT signaling pathway via MSR1, significantly upregulating the expression of the chemokine CCL2, thereby amplifying the macrophage-mediated inflammatory cascade. By inhibiting MSR1 or blocking the PI3K / AKT signaling pathway, the macrophage accumulation, inflammation activation, and renal tissue structural damage induced by oligomeric PLA MPs can be significantly reduced, thereby treating PLA MPs-induced kidney injury. This invention reveals for the first time the key regulatory role of the MSR1-PI3K / AKT signaling axis in PLA MPs-induced kidney injury, providing a new molecular target and intervention strategy for the prevention and treatment of degradable MPs-related kidney diseases.

The invention belongs to the field of new application of medicines, and particularly relates to application of verofenib in preparation of medicines for treating renal fibrosis diseases. It is found for the first time that the vilorafenib is combined with the EIF4A1 protein to inhibit the activity of renal fibers, the vilorafenib can be used as a potential anti-renal-tissue-fibrosis medicine, and a new thought is provided for research of anti-organ or tissue-fibrosis medicines.

According to the lipid metabolism pathway marker of GK in obesity-related glomerulonephritis podocyte damage and the diagnosis application, the expression level of glycerol kinase in a tested sample is detected, and the expression level is compared with the corresponding expression level in a reference sample; diagnosis information for representing the abnormal state of the podocyte lipid metabolism pathway of the obesity-related glomerulonephritis is obtained based on the comparison result, and the expression level comprises the messenger ribonucleic acid expression level of glycerol kinase, the protein expression level or the combination of the messenger ribonucleic acid expression level and the protein expression level. A test sample comprises at least one of a kidney tissue sample, a serum sample, a plasma sample, a whole blood sample or a urine sample, and the related state of podocyte damage of obesity-related glomerulonephritis is subjected to molecular level characterization from the lipid metabolism pathway level; the method has the advantages of being clear in diagnosis directivity, suitable for multiple sample types, flexible in detection mode and capable of being used for disease layering and dynamic evaluation.

COL3A1 as a marker for detecting kidney stones and its application. The application discloses a new use of COL3A1 as a specific detection marker for kidney stones, and a kit, a detection method and application for detecting kidney stones based on the expression level of COL3A1. Through cross-species transcriptome sequencing, qRT-PCR, Western blot and immunofluorescence verification of human kidney stone clinical samples and mouse kidney stone models, it is confirmed that COL3A1 is significantly up-regulated in kidney tissues of kidney stone lesions, and can be used as a molecular marker for distinguishing kidney stone patients from healthy people. The detection method provided by the application has high specificity and sensitivity, and can realize early screening, auxiliary diagnosis, disease monitoring and recurrence risk assessment of kidney stones, and provides a new molecular target and non-invasive detection scheme for clinical diagnosis of kidney stones.

The invention relates to the technical field of biology, in particular to a method for rapidly preparing a hiPSC-sourced kidney organ. The method comprises the following steps: gradually carrying out induced differentiation, digestion and centrifugation on stem cells by adopting a middle mesoderm induction culture medium and other culture mediums to obtain a cell mixture, incubating, and carrying out induced culture by adopting a kidney precursor induction culture medium and the like to obtain the kidney organ. The culture medium, the cell factors and the like used in the method are conventional reagents, the production cycle of the kidney precursor organ-like globules can be stably controlled within 18 days, and the globules can be continuously differentiated into kidney organ-like mature bodies after resuscitation; and an important cell population related to kidney tissues and having appearance morphological characteristics highly consistent with those of a mature body which is directly differentiated from hIPSC into a kidney organoid without cryopreservation. According to the kidney organ product provided by the invention, the production of kidney organs can be increased through the steps of cryopreservation and resuscitation, the difference between batches is reduced, and the standardization and large-scale production process can be realized.

The application of SCAP inhibitor in the preparation of drugs for treating and / or preventing renal lipotoxic injury belongs to the technical field of medicine. The present study proves that the expression of SCAP in the kidney tissue of mice with renal lipotoxic injury is significantly up-regulated at the animal level; it is also proved that the SCAP level is significantly increased after high glucose and high fat induction at the level of podocytes, and further promotes cell injury and lipid deposition; after using SCAP interfering virus or inhibitors Fatostatin and Betulin, the inflammation injury and lipid deposition of podocytes can be effectively alleviated, and the mechanism is related to the inhibition of SREBP-1c / NLRP3 pathway. The technical scheme is that the SCAP inhibitor is applied in the preparation of drugs for treating and / or preventing renal lipotoxic injury.